Cagrilintide: The Long-Acting Amylin Analogue Transforming Combination Obesity Research

Cagrilintide (AM833, Novo Nordisk) is a long-acting acylated amylin analogue designed for once-weekly subcutaneous administration. Amylin (islet amyloid polypeptide, IAPP) is a peptide co-secreted with insulin from pancreatic β-cells that signals postprandial satiety through area postrema and nucleus tractus solitarius (NTS) receptors in the brainstem. Cagrilintide's structural modifications — including an Lys26 acylation similar to semaglutide's fatty acid extension — extend its half-life to ~7 days, enabling the weekly dosing format required for Phase 3 development.

Amylin Biology and Satiety Mechanism

Amylin is released proportionally to the insulin response after meals. It acts on amylin receptors (CTR/RAMP complexes) in the brainstem and hypothalamus to:

• Signal gastric satiety through NTS projections to the hypothalamus
• Slow gastric emptying (additive to GLP-1 effects)
• Suppress glucagon secretion in the postprandial period
• Reduce meal size and frequency

The critical mechanistic insight is that amylin/cagrilintide acts primarily through brainstem satiety circuits (area postrema → NTS → hypothalamus), while GLP-1 acts primarily through hypothalamic and vagal pathways. This anatomical separation means the two mechanisms are genuinely additive rather than redundant — the combination achieves greater satiety signalling than either compound alone.

CagriSema: The Combination Data

The CagriSema combination (cagrilintide + semaglutide) represents the most advanced development of the amylin/GLP-1 combination strategy. Phase 2 FLOW trial data published in The Lancet (2024) showed:

• Mean weight reduction of ~15.6% at 32 weeks for the 2.4 mg sema + 2.4 mg cagrilintide combination
• Phase 3 REDEFINE trials have published ~25.1% weight reduction at 68 weeks for the highest CagriSema dose combination
• Importantly: the combination produced greater weight loss than either component alone — confirming mechanistic synergy rather than simple additive dosing effect
• Metabolic improvements (HbA1c, fasting glucose, lipids) proportional to and exceeding predictions from weight loss alone

The ~25% weight loss positions CagriSema alongside retatrutide as producing the highest efficacy among pharmacological obesity treatments developed to date.

Mechanism of Synergy Explained

The exceptional weight-loss outcomes of the CagriSema combination stem from anatomically distinct but functionally complementary satiety pathways:

• Semaglutide (GLP-1) → hypothalamic arcuate nucleus → appetite and energy balance regulation
• Cagrilintide (amylin) → brainstem area postrema/NTS → gastric fullness signalling

Combined, they engage satiety circuits that neither activates alone, creating a broader and more sustained reduction in appetite and food intake than single-mechanism approaches.

Side Effects and Tolerability

Cagrilintide's tolerability profile is similar to GLP-1 agonists but with distinct nausea characteristics. The combination with semaglutide does not appear to multiplicatively worsen GI adverse events — additive but manageable GI effects are observed. Nausea is the most common adverse event (30–45% in combination trial arms). The slow escalation titration protocol applied to the combination reduces early GI burden.

Comparison to Standalone GLP-1 Agonists

CagriSema's superiority over semaglutide alone (~25% vs ~15% weight loss) at comparable semaglutide doses demonstrates that amylin co-agonism adds meaningful independent efficacy. This suggests a general principle: achieving maximum weight-loss outcomes will likely require multi-mechanism combinations (GLP-1 + amylin, or GLP-1/GIP/glucagon) rather than single-receptor optimisation.

Frequently Asked Questions

How does cagrilintide compare to pramlintide (Symlin)?

Pramlintide is a short-acting amylin analogue requiring injection at each meal (3x daily). Cagrilintide's acylation and structural modifications extend the half-life to ~7 days, enabling once-weekly dosing comparable to semaglutide — a critical advance for patient compliance and trial design.

Is cagrilintide approved as a standalone treatment?

No. Cagrilintide is primarily developed as the amylin component of the CagriSema combination. Standalone data exists but its primary development path is as a combination therapy.

References

• Enebo LB, et al. (2024). Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide. The Lancet.
• Rubino D, et al. (2024). Effect of cagrilintide 2.4 mg with semaglutide 2.4 mg in obesity. The Lancet.
• Kruse T, et al. (2022). Discovery and characterisation of the long-acting amylin analogue cagrilintide. Journal of Medicinal Chemistry.